title: Liposome-mediated targeting of enzymes to cancer cells for site-specific activation of prodrugs: comparison with the corresponding antibody-enzyme conjugate.
abstract: OBJECTIVE
  Immunoenzymosomes are tumor-targeted immunoliposomes bearing enzymes on their surface. These enzymes are capable of converting relatively nontoxic prodrugs into active cytostatic agents. The aims of this study were to compare the enzyme delivery capability of immunoenzymosomes with that of the corresponding antibody-enzyme conjugate and to evaluate whether immunoenzymosomes are able to mount a strong bystander effect.
  
  
  METHODS
  Immunoenzymosomes exposing Fab' fragments of the monoclonal antibody 323/A3 and the bacterial enzyme beta-glucuronidase or the corresponding antibody-enzyme conjugate were incubated with OVCAR-3 cells (human ovarian carcinoma cells). Cell-associated enzymatic activity and the in vitro antiproliferative effect of a glucuronide prodrug of doxorubicin (DOX-GA3) were determined.
  
  
  RESULTS
  At equal numbers of carrier units, the cell-associated enzymatic activity achieved by using immunoenzymosomes was 15-fold higher than that obtained after incubation with the corresponding antibody-enzyme conjugate. Increasing the amount of antibody-enzyme conjugate added to the cells could not compensate for their lower enzyme delivery capability. Immunoenzymosomes were able to induce inhibition of cell growth not only of tumor cells to which immunoenzymosomes were bound but also of a large number of neighboring cells.
  
  
  CONCLUSIONS
  Immunoenzymosomes are able (a) to target prodrug-converting enzymes more efficiently to tumor cells than the corresponding antibody-enzyme conjugate and (b) to mount a strong bystander effect.
authors.affiliation: Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, Utrecht, The Netherlands.
authors.forename: María José
authors.initials: MJ
authors.lastname: Fonseca
authors.forename: Joycelyn C
authors.initials: JC
authors.lastname: Jagtenberg
authors.forename: Hidde J
authors.initials: HJ
authors.lastname: Haisma
authors.forename: Gert
authors.initials: G
authors.lastname: Storm
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000737:chemistry*; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000378:metabolism / Q000494:pharmacology*; D045744:Cell Line, Tumor; D004317:Doxorubicin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000378:metabolism / Q000494:pharmacology*; D016503:Drug Delivery Systems; D005260:Female; D005965:Glucuronates / Q000008:administration & dosage / Q000378:metabolism / Q000494:pharmacology*; D005966:Glucuronidase / Q000737:chemistry / Q000378:metabolism*; D006801:Humans; D008081:Liposomes; D051379:Mice; D011355:Prodrugs / Q000008:administration & dosage / Q000378:metabolism / Q000494:pharmacology*
chemical_list: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D005965:Glucuronates; D008081:Liposomes; C407038:N-(4-doxorubicin-N-carbonyl(oxymethyl)phenyl)-O-glucuronyl carbamate; D011355:Prodrugs; D004317:Doxorubicin; D005966:Glucuronidase